The Quantellect read.As of Nov 19, 2026, 14 active firms cover Arrowhead Pharmaceuticals Inc: 11 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $46.00 to $126.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $99.07 sits 130% above the current $43.13. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 11 over recent months. On the fundamentals, the Street sees revenue growth near -43% this year and -29% next, consensus EPS building from about $-1.52 next quarter toward $-3.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy00%
Buy1179%
Neutral321%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$99.07
+129.7% upside
Average target across 14 active firms as of Nov 19, 2026 vs $43.13 current
Highest Target$126.00
Average Target$99.07
Lowest Target$46.00
Detailed analyst forecasts for ARWR
Showing 1–15 of 15 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 11 of 14 active firms rate ARWR a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ARWR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.52
Range $-1.82 – $-1.30 · 6 analysts · +63% YoY
Next period, 6 analysts expect Arrowhead Pharmaceuticals Inc to earn $-1.52 a share (range $-1.82 – $-1.30), versus $-0.93 a year earlier. Full-year consensus is $-5.66, growing to $-3.60 the year after.
REVENUE · NEXT QUARTER
$54.5M
Range $23.0M – $127.7M · 6 analysts · -69% YoY
Revenue is expected to reach $54.5M (range $23.0M – $127.7M), -69.0% year-over-year. Full-year consensus is $314.6M, rising to $541.7M next year.
Top analysts covering Arrowhead Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARWR.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$38.00-11.9% to target
Overall win rate
49%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Buy
$100.00+131.9% to target
Overall win rate
49%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
No targeton ARWR
Overall win rate
51%
+ Follow
#4
Keay Nakae
Chardan Capital · Rank #130
Buy
$115.00+166.6% to target
Overall win rate
41%
+ Follow
#5
Jason Gerberry
B of A Securities · Rank #160
Buy
$100.00+131.9% to target
Overall win rate
47%
+ Follow
ARWR stock forecast FAQ
What is ARWR's average 12-month price target?+
The 14 active firms with a live target average $99.07 for Arrowhead Pharmaceuticals Inc over the next 12 months, ranging from a $126.00 high to a $46.00 low, as of Nov 19, 2026.
Is ARWR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ARWR?+
The Street-high target is $126.00 (Piper Sandler), and the Street-low is $46.00 (Bernstein). The average of all 14 active-firm targets is $99.07.
How many active Wall Street firms cover ARWR?+
14 active firms have a recognized rating on Arrowhead Pharmaceuticals Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ARWR?+
Among analysts who currently cover ARWR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $38.00 target.
What is Arrowhead Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.52 per share (range $-1.82 – $-1.30) across 6 analysts. Full-year EPS is projected at $-5.66, rising to $-3.60 the following year.
How much revenue is Arrowhead Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $54.5M (range $23.0M – $127.7M). Full-year revenue is projected at $314.6M, growing to $541.7M next year.
Have analysts been upgrading or downgrading ARWR lately?+
As of Nov 19, 2026, 11 of 14 active firms rate ARWR a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARWR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.